Form 4: Viemed Healthcare VP of Sales Reports Equity Transactions

Viemed Healthcare's VP of Sales, Jerome Cambre, reported the vesting and grant of equity awards, including restricted stock units and phantom share units.

Summary

• Jerome Cambre, Vice President of Sales at Viemed Healthcare, Inc. (VMD), reported multiple equity transactions.
• On January 17, 2026, 8,525 Restricted Stock Units (RSUs) and 2,132 Phantom Share Units, originally granted on January 17, 2023, vested.
• Concurrently, 2,784 common shares were disposed of to satisfy tax obligations, and 2,132 common shares were disposed of for the cash settlement of phantom shares, both at a per-share value of $7.33.
• Following these transactions, the beneficial ownership of common shares was 89,932.
• On January 19, 2026, Mr. Cambre was granted 40,676 new RSUs and 10,169 new Phantom Share Units, which will vest in three equal annual installments starting one year from the grant date.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation activities for a company executive, including the vesting of prior awards and the grant of new ones, indicating ongoing executive retention and incentive alignment.

Positives

• The vesting of 8,525 Restricted Stock Units and 2,132 Phantom Share Units indicates the successful achievement of prior compensation milestones.
• The grant of 40,676 new Restricted Stock Units and 10,169 new Phantom Share Units aligns executive incentives with future company performance and aids in executive retention.

Negatives

• The disposition of 2,784 common shares for tax withholding and 2,132 common shares for cash settlement of phantom shares represents a reduction in direct share ownership by the executive, though it is a standard practice for equity compensation.

Future Outlook

The newly granted 40,676 Restricted Stock Units and 10,169 Phantom Share Units will vest in three equal annual installments, beginning on January 19, 2027.

Industry Context

NA

Stakeholder Impact

• Shareholders: The issuance of new equity awards could lead to minor dilution but also strengthens the alignment of executive incentives with long-term company performance.
• Employees (specifically the reporting person): The vesting and new grants represent significant compensation, reinforcing retention and motivation.

Next Steps

• Vesting of 40,676 Restricted Stock Units in three equal annual installments beginning January 19, 2027.
• Vesting of 10,169 Phantom Share Units in three equal annual installments beginning January 19, 2027.

Key Dates

Recommendation

This Form 4 details routine equity compensation for a Vice President of Sales, involving the vesting of previously granted awards and the issuance of new ones. Such transactions are standard practice for executive incentive programs and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The transactions reflect ongoing executive alignment with shareholder interests rather than a significant market event.

Keywords

Viemed Healthcare, VMD, Form 4, Insider Trading, Restricted Stock Units, Phantom Shares, Equity Compensation, Jerome Cambre